Julia Olegovna Fedotova, Vagif Soultanov, Tamara Nikitina and Victor Roschin
Department of Neuroendocrinology, I.p. Pavlov Institute of Physiology RASci, St. Petersburg, Russia
The present preclinical study was designed to examine the effects of prolonged Ropren® administration in an animal model of memory impairment induced by β-amyloid-peptide-(25-35) injection in male rats after gonadectomy. The experimental model of Alzheimer's disease was created by intracerebroventricular injection of β-amyloid-peptide-(25-35) into gonadectomized (GDX) rats. Ropren® (8.6 mg/kg, per os, once daily, 28 days) was administered to the GDX rats and GDX rats treated with testosterone propionate. Memory impairment was assessed using the passive avoidance test and the Morris water maze and behavior was assessed using the open field test. Treatment with Ropren® significantly improved and restored the cognitive ability of GDX rats with Aβ 25-35-induced amnesia in the passive avoidance test and Morris water maze. Co-administration of Ropren® with TP exerted a markedly synergistic memory-enhancing effect in the GDX rats with Aβ 25-35-induced amnesia on the same models of memory testing. These results indicate that Ropren® has a marked memory-enhancing action in the experimental model of Alzheimer's disease in male rats with altered levels of androgens. Further clinical studies should be carried out to further evaluate the memory-enhancing effect of Ropren® treatment for monotherapy or adjuvant therapy of Alzheimer's disease in men with hypogonadism.
Keywords: Alzheimer's disease, polyprenols, long-chain isoprenoid alcohols, dolichols, Ropren®, memory, gonadectomy, testosterone.